CD137 Protein, Human, Recombinant (His & Fc Tag)

1/2
Price:
Size:
Number:

CD137 Protein, Human, Recombinant (His & Fc Tag): Product Information

Purity
> 95 % as determined by SDS-PAGE
Endotoxin
< 1.0 EU per μg of the protein as determined by the LAL method
Activity
Measured by its binding ability in a functional ELISA.
Immobilized recombinant Human 4-1BB-Fch (Cat:10041-H03H) at 10 μg/ml(100 μl/well) can bind humanS4-Fc3L3-TNFSF9/Biotin (Cat:15693-H01H) with a linear range of 1.28-20 μg/ml.
Protein Construction
A DNA sequence encoding the N-terminal fragment (Met 1-Gln 186) of the extracellular domain of human 4-1BB (NP_001552.2) was fused with the C-terminal polyhistidine-tagged Fc region of human IgG1 at the C-terminus.
Accession#
Expressed Host
HEK293 Cells
Species
Human
Predicted N Terminal
Gln 25
Molecule Mass
The recombinant human 4-1BB/Fc chimera is a disulfide-linked homodimeric protein. The reduced monomer consists of 409 amino acids and has a calculated molecular mass of 45.2 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rh4-1BB/Fc monomer is approximately 60-65 kDa due to glycosylation.
Formulation
Lyophilized from sterile PBS, pH 7.4
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

CD137 Protein, Human, Recombinant (His & Fc Tag): Images

Measured by its binding ability in a functional ELISA. Immobilized recombinant Human 4-1BB-Fch (Cat:10041-H03H) at 10 μg/ml(100 μl/well) can bind humanS4-Fc3L3-TNFSF9/Biotin (Cat:15693-H01H) with a linear range of 1.28-20 μg/ml.

CD137 Protein, Human, Recombinant (His & Fc Tag): Alternative Names

4-1BB Protein, Human; CD137 Protein, Human; CDw137 Protein, Human; ILA Protein, Human

CD137 Background Information

CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor necrosis factor receptor–associated factors (TRAFs), the adaptor protein which mediates downstream signaling events including the activation of NF-kappaB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T-cell activation and growth, as well as monocyte proliferation and B-cell survival, and plays an important role in the amplification of T cell-mediated immune responses. In addition, CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors. Crosslinking of CD137 on activated T cells has shown promise in enhancing anti-tumor immune responses in murine models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials. Soluble forms of CD137 (sCD137) are generated by differential splicing. sCD137 can bind to CD137 ligand to antagonize the costimulatory activities of the membrane-bound CD137 and reduce T cell proliferation and IL-2 secretion.
Full Name
tumor necrosis factor receptor superfamily, member 9
Research Areas
References
  • Sica G, et al. (1999) Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy. Arch Immunol Ther Exp (Warsz). 47(5): 275-9.
  • Nam KO, et al. (2005) The therapeutic potential of 4-1BB (CD137) in cancer. Curr Cancer Drug Targets. 5(5): 357-63.
  • Wang Q, et al. (2008) Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J. 49(2): 192-200.
  • Melero I, et al. (2008) Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci. 29(8): 383-90.
  • Thum E, et al. (2009) CD137, implications in immunity and potential for therapy. Front Biosci. 14: 4173-88.
  • Human and Mouse CD137 Have Predominantly Different Binding CRDs to Their Respective Ligands
    Author
    Yi, L;Zhao, Y;Wang, X;Dai, M;Hellström, KE;Hellström, I;Zhang, H;
    Year
    2014
    Journal
    PLoS ONE
    Application
    binding
  • CD137-CRDI is not necessary in the role of contacting its natural ligand
    Author
    Yi, L;Yan, Z;Jia, H;Wang, X;Zhao, Y;Zhang, H;
    Year
    2016
    Journal
    Immunol. Cell Biol.
    Application
    ELISA
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait